T. Alex Perkins, Philippe Buchy, Thomas W. Scott, Veasna Duong, Louis Lambrechts, Quirine A. ten Bosch, Amy C. Morrison, Benjamin M. Althouse, Uriel Kitron, Lance A. Waller, Alun L. Lloyd, Hannah E. Clapham, Gonzalo M. Vazquez-Prokopec, Eck Institute for Global Health, University of Notre Dame [Indiana] (UND), Johns Hopkins Bloomberg School of Public Health [Baltimore], Johns Hopkins University (JHU), Interactions Virus-Insectes - Insect-Virus Interactions (IVI), Centre National de la Recherche Scientifique (CNRS)-Institut Pasteur [Paris], Institut Pasteur du Cambodge, Réseau International des Instituts Pasteur (RIIP), University of Washington [Seattle], New Mexico State University, North Carolina State University [Raleigh] (NC State), University of North Carolina System (UNC), Emory University [Atlanta, GA], University of California [Davis] (UC Davis), University of California, This research was funded by a grant from the US National Institutes of Health – National Institute of Allergy and Infectious Diseases (NIH/NIAID (https://www.niaid.nih.gov/)) award number P01AI098670 (to TWS). Research leading to results on infectiousness in asymptomatic individuals received funding from the European Union Seventh Framework Programme (FP7/2007/2011) under Grant Agreement 282 378. LL is supported by the French Government’s Investissement d’Avenir program, Laboratoire d’Excellence Integrative Biology of Emerging Infectious Diseases (grant ANR-10-LABX-62-IBEID (http://www.agence-nationale-recherche.fr/)) and the City of Paris (http://www.paris.fr/) Emergence(s) program in Biomedical Research. BMA thanks Bill and Melinda Gates through the Global Good Fund (http://www.globalgoodfund.org/). QAtB, BMA and TAP received support from Intellectual Ventures (http://www.intellectualventures.com/). ALL is supported by grant R01-AI091980 from the National Institutes of Health (www.nih.gov/) and by the National Science Foundation (www.nsf.gov) (RTG/DMS - 1246991). HEC is supported by National Institutes of Health (www.nih.gov/) under award no. 5R01AI102939-03. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., ANR-10-LABX-0062,IBEID,Integrative Biology of Emerging Infectious Diseases(2010), European Project: 282378,EC:FP7:HEALTH,FP7-HEALTH-2011-single-stage,DENFREE(2012), Ferguson, Neil M, Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), and University of California (UC)
Despite estimates that, each year, as many as 300 million dengue virus (DENV) infections result in either no perceptible symptoms (asymptomatic) or symptoms that are sufficiently mild to go undetected by surveillance systems (inapparent), it has been assumed that these infections contribute little to onward transmission. However, recent blood-feeding experiments with Aedes aegypti mosquitoes showed that people with asymptomatic and pre-symptomatic DENV infections are capable of infecting mosquitoes. To place those findings into context, we used models of within-host viral dynamics and human demographic projections to (1) quantify the net infectiousness of individuals across the spectrum of DENV infection severity and (2) estimate the fraction of transmission attributable to people with different severities of disease. Our results indicate that net infectiousness of people with asymptomatic infections is 80% (median) that of people with apparent or inapparent symptomatic infections (95% credible interval (CI): 0–146%). Due to their numerical prominence in the infectious reservoir, clinically inapparent infections in total could account for 84% (CI: 82–86%) of DENV transmission. Of infections that ultimately result in any level of symptoms, we estimate that 24% (95% CI: 0–79%) of onward transmission results from mosquitoes biting individuals during the pre-symptomatic phase of their infection. Only 1% (95% CI: 0.8–1.1%) of DENV transmission is attributable to people with clinically detected infections after they have developed symptoms. These findings emphasize the need to (1) reorient current practices for outbreak response to adoption of pre-emptive strategies that account for contributions of undetected infections and (2) apply methodologies that account for undetected infections in surveillance programs, when assessing intervention impact, and when modeling mosquito-borne virus transmission., Author summary Most dengue virus infections result in either no perceptible symptoms or symptoms that are so mild that they go undetected by surveillance systems. It is unclear how much these infections contribute to the overall transmission and burden of dengue. At an individual level, we show that people with asymptomatic infections are approximately 80% as infectious to mosquitoes as their symptomatic counterparts. At a population level, we show that approximately 88% of infections result from people who display no apparent symptoms at the time of transmission. These results suggest that individuals undetected by surveillance systems may be the primary reservoir of dengue virus transmission and that policy for dengue control and prevention must be revised accordingly.